We are excited to announce the 10th CNS Partnering & Deal-Making Conference, to be held September 11-12, 2017 in Boston, MA.
Over the years, this partnering and business development conference has provided an opportunity for all stakeholders in the field to network and explore potential collaborations. Global biotechnology and pharmaceutical companies, patient groups and foundations, government agencies, investors, and regulatory folks have gathered to discuss partnering strategies as well as emerging research areas and trends to keep an eye on.
This meeting seeks to form discussion on all topics from bench to bedside, from changing paradigm in scientific approaches in CNS disorders to partnerships for open innovation to pricing and reimbursement considerations. Colleagues will dialogue and form new relationships in order to forge a path forward into the future of neuroscience.
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions: Neuroinflammation, Neuroimaging & Translational Biomarkers
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for future
10th CNS Partnering & Deal-making
I. What’s New in CNS – Targets, Models, Assays, etc.
II. Industry Partnering with Academia & CROs to Advance Research
III. CNS Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities
We hope to see you in Boston!
The 2017 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
SRI provides broad expertise in antiviral and vaccine efficacy /safety studies, utilizing its extensive collection of human and animal Influenza isolates, and providing: in vitro evaluation, customizable in vivo models, vaccine discovery /development, discovery tools in ferret model. SRI offers research, discovery /development CRO services, Phase I Clinical Trials.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.